CME Group (CME) Stock Faces Dividend Coverage Questions Despite 62.7% Net Margin Reinforcing Bull Case

CME Group (CME) has just posted its Q2 2026 numbers with revenue of US$1,706.2 million and basic EPS of US$2.89, set against a trailing twelve month backdrop of US$6.76 billion in revenue and EPS of US$11.77. The company has seen quarterly revenue move between US$1,534.4 million and US$1,876.2 million over the last six reported periods, while basic EPS has ranged from US$2.49 to US$3.25, giving investors a clear read on earnings power heading into this latest update. With trailing net margins at 62.7%, this quarter focuses on how CME Group is converting its revenue base into profit and what that implies for the durability of those margins.

See our full analysis for CME Group.

With the headline figures on the table, the next step is to compare these results with the widely followed narratives around CME Group's growth, profitability and income profile to assess which views are supported and which are challenged by the latest numbers.

See what the community is saying about CME Group

Margins stay high at 62.7%

• Over the last 12 months, CME Group converted US$6.76 billion of revenue into US$4.24 billion of net income, giving it a net margin of 62.7% compared with 57.9% a year earlier.
• Consensus narrative highlights CME Group’s strong demand for risk management and growing international and retail activity, and the current 62.7% net margin gives numbers behind that story, even as:
  • Five year earnings have grown 12% per year with the latest year at 13.8%, which lines up with the idea of a business that has been handling higher volumes efficiently.
  • At the same time, analysts expect margins to ease to 60.9% over three years, so the current margin level sits above what the consensus narrative is building into its longer term model.

High margins are a big part of why many investors watch CME Group closely, since they show how much of every US$1 of revenue is keeping for shareholders.

Earnings growth vs slower forecasts

• On a trailing basis, earnings of US$4.24 billion and EPS of US$11.77 reflect 13.8% earnings growth over the past year and about 12% per year over five years, while forward estimates point to around 5.4% annual earnings growth and 5.5% revenue growth.
• Analysts' consensus view sees strong historical growth giving CME Group a solid base, yet the forecast step down to mid single digit growth creates a contrast that matters for expectations:
  • Supporters of the bullish narrative point to record contract activity, new products and global expansion as drivers that helped deliver the multi year 12% earnings growth rate.
  • Those same forecasts now building in roughly 5.4% annual earnings growth and EPS of US$13.42 by 2029 imply the market is already tempering that bullish pace in its models.

For you as an investor, the key question is whether CME Group’s past double digit earnings growth or the mid single digit forecasts feel more representative of what you expect from the business over time.

Bulls argue that CME Group’s mix of high margins and global volume growth could support a stronger case than these mid single digit forecasts suggest, especially if key contracts stay active and new products keep gaining traction. 🐂 CME Group Bull Case

P/E discount and dividend coverage watch

• CME Group trades on a trailing P/E of 21.3x compared with 39x for the US Capital Markets industry and 26.2x for peers, while offering a 4.55% dividend yield that is not well covered by free cash flow on a trailing 12 month view.
• Critics in a more bearish narrative focus on the mix of modest forecast growth and cash flow demands, and the current numbers give some backing to those concerns:
  • The trailing P/E below both industry and peer averages lines up with the idea that the market is not paying a premium multiple even after several years of earnings growth.
  • The 4.55% yield, combined with weaker free cash flow coverage, means income focused investors may want to look closely at how much headroom exists if growth stays around the forecast 5.4% and 5.5% ranges.

If you are weighing that trade off between valuation, growth and income, it helps to compare CME Group’s 21.3x P/E and 4.55% yield with what you can find in other capital markets stocks and in wider income oriented opportunities. 🐻 CME Group Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for CME Group on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If the mix of high margins, moderated forecasts and income trade offs around CME Group feels finely balanced, now is the time to look through the numbers yourself and weigh both sides of the story, then factor in the 3 key rewards and 2 important warning signs

See What Else Is Out There

CME Group combines high margins with only mid single digit forecast growth and a 4.55% dividend yield that is not well covered by free cash flow.

If you want income that looks more comfortably supported by cash generation, it is worth urgently comparing CME Group with the 7 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com